Role of Akt signaling in resistance to DNA-targeted therapy

Table 1 Drugs targeting phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin pathway

PI3K/Akt/mTOR subgroups	Agents	Clinical Stage
Pan-PI3K inhibitors	XL147	Phase II
	BKM120	Phase III
	GDC0941	Phase II
Rapalogues (mTORC1 inhibitors)	Sirolimus	Phase III
	Everolimus	Approved
	Temsirolimus	Approved
	Ridaforolimus	Phase III
mTORC1/2 inhibitors	INK128	Phase II
	AZD8055	Phase I
	OSI027	Phase I
PI3K–mTOR inhibitors	BEZ235	Phase II
	XL765	Phase II
	GSK1059615	Phase I
Isoform-specific PI3K inhibitors	CAL-101 (p110δ)	Phase III
	INK1117 (p110α)	Phase I
	BYL719 (p110α)	Phase II
Akt inhibitors	Perifosine	Phase III
	MK-2206	Phase II
	GDC0068	Phase II
	GSK690693	Phase I

PI3K: Phosphatidylinositol 3 kinase; mTOR: Mammalian target of rapamycin.